NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 65 Years

Referral Letter Required


Population Exclusion(s)



Severe Insulin Resistance;
Growth Hormone Inhibition;

Recruitment Keyword(s)



Insulin Receptor Mutation;
Partial Lipodystrophy

Investigational Drug(s)


Investigational Device(s)



Drug: Pegvisomant

Supporting Site

National Institute of Diabetes and Digestive and Kidney Diseases


Lipodystrophy (LD) syndromes are a group of rare disorders that affect how a person s body can store and use fat tissue. Many people with LDs become severely insulin resistant. Some people are insulin resistant because of a variant in the insulin receptor gene. Insulin resistance causes many health problems.


To learn if blocking the effects of growth hormone in the body will help people with severe insulin resistance.


Adults aged 18 to 65 years with either a known variant in the insulin receptor gene or with a diagnosis of partial LD.


Participants will have 2 hospital stays, about 1 month apart. Each stay will be 3 or 4 nights.

During each hospital stay, participants will have many tests. They will have a physical exam with blood tests. They will have all of their urine collected for a 24-hour period. They will have scans to measure their muscle, bone, and fat tissues. They will have tests to measure metabolism and insulin sensitivity. They may have an optional biopsy of fat tissue.

During the first hospital visit, participants will learn how to give themselves shots of a drug (pegvisomant) that blocks growth hormone. The drug is injected under the skin. Participants will continue to give themselves these shots once a day at home.

After the first hospital visit, participants will talk on the phone with members of the study team once each week. After 2 weeks they will have blood drawn for tests.

Participants will stop the shots after the second hospital visit.

--Back to Top--



To be eligible to participate in this study, an individual must meet all the following criteria:


--Known pathogenic variant in the insulin receptor gene, either dominant negative or recessive, OR

--Clinical diagnosis of partial lipodystrophy based on reduction in adipose tissue outside the normal range in selected adipose depots (including, at a minimum, the gluteofemoral depot) with preservation of adipose tissue in other depots.

-Male or female, aged 18-65 years.

-Completed linear growth and puberty.


An individual who meets any of the following criteria will be excluded from participation in this study:

-Use of niacin or other drugs that directly affect lipolysis within 8 weeks prior to enrollment.

-Patients taking anticoagulants (blood thinning medications).

-Use of non-steroidal anti-inflammatory medications (e.g., aspirin, ibuprofen) 2 weeks prior to the biopsy date (in patients who choose to undergo biopsy).

-Changes in medications for diabetes or dyslipidemia within 2 weeks prior to enrollment.

-Pregnancy or lactation.

-For females of reproductive potential: inability or unwillingness to use contraception during study participation and for an additional 1 month after the end of pegvisomant administration.

-For males of reproductive potential: inability or unwillingness to use condoms or other methods to ensure effective contraception with partner during the study and for an additional 1 month after the end of pegvisomant administration.

-Known allergic reactions pegvisomant or any of its components.

-Clinically significant liver disease, evidenced by any of the following:

--ALT or AST >3 times the upper limit of normal at screening.

--Current known liver disease other than steatohepatitis (e.g., autoimmune or viral hepatitis).

--History of cirrhosis

-Triglycerides >1500 mg/dL (non-fasting) or >1000 mg/dL (fasting) at screening.

-In subjects with partial lipodystrophy only, Hemoglobin A1c >10% at screening.

-Any other medical condition or medication that, in the judgement of the investigator, will increase risk to the subject or impede the measurement of study outcomes.

-Inability of subject to understand or the unwillingness to sign a written informed consent document.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Rebecca J. Brown, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIHBC 10 - CRC BG RM 6-5942
(301) 594-0609

Megan S. Startzell, R.N.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health
Building 10
Room 5-5750
10 Center Drive
Bethesda, Maryland 20892
(301) 402-6371

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--